<table>
<thead>
<tr>
<th>TOPIC</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PLATELETS</strong></td>
</tr>
<tr>
<td>Effective Pathogen Inactivation in Triple Set Kits for Platelets suspended in Platelet Additive Solution (PASIII)</td>
</tr>
<tr>
<td>Storage Study of Apheresis Platelets in Additive Solution after Photochemical Treatment using a Novel Triple Storage Set</td>
</tr>
<tr>
<td>In Vitro Storage Quality of Triple Dose Apheresis versus Single Dose Whole Blood Derived Photochemically treated using a Novel Triple Storage Set</td>
</tr>
<tr>
<td>Evaluation of Apheresis Platelets Processed with the INTERCEPT Blood System for Platelets Triple Storage Set</td>
</tr>
<tr>
<td>Operational Validation of the Preparation of Pathogen Inactivated Double Dose Buffy Coat Platelet Concentrates</td>
</tr>
<tr>
<td>Effectiveness of Amotosalen/UVA Light Pathogen-Reduced Platelets Transfused to Adult Patients</td>
</tr>
<tr>
<td>Comparison of Amotosalen/UVA Light Pathogen-Reduced Platelets in 100% Plasma versus Amotosalen/UVA Light Pathogen-Reduced Platelets in PAS: In Vitro Functional and Survival Parameters</td>
</tr>
<tr>
<td>Implementation of Double Dose Pathogen Inactivated Platelets in Routine with Productivity and Cost Optimization</td>
</tr>
<tr>
<td>Comparative Efficacy Analysis of Y-irradiated Platelet Concentrates Transfusions, prepared in 100% Donor Plasma and in Addictive Solution by using Tromboelastography</td>
</tr>
<tr>
<td><strong>PLASMA</strong></td>
</tr>
<tr>
<td>Pathogen Inactivation of Whole Blood (WB) Derived Plasma with Amotosalen/UVA: Results from a Validation In Vitro Study</td>
</tr>
<tr>
<td>Evaluation of Pathogen Reduced (Amotosalen-UVA) Pooled Cryoprecipitate and Cryoprecipitate-Poor Plasma</td>
</tr>
<tr>
<td><strong>RBC</strong></td>
</tr>
<tr>
<td>Robust Inactivation of Duck Hepatitis B Virus with Amustaline/GSH in Whole Blood</td>
</tr>
<tr>
<td>Robustness of the INTERCEPT Blood System for Red Blood Cells</td>
</tr>
</tbody>
</table>